Home » Business News » 2013 » November » November 7, 2013

Bavarian Nordic to Host Third Quarter 2013 Results Conference Call

November 7, 2013 - London

KVISTGAARD, Denmark - November 7, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 third quarter results on Thursday, November 14, 2013.

The company will host a conference call at 2:00 pm CET (8:00 am EST) on the same day. President and CEO, Anders Hedegaard will present the interim results followed by a Q&A session with participation of the Company's executive management.

Dial-in numbers for the conference call are:

Denmark: +45 32 72 80 18
UK: +44 (0) 844 571 8957
USA: +1 866 682 8490

A webcast of the conference call will be broadcasted simultaneously at On this page, the accompanying presentation will be available prior to the conference call.

Rolf Sass Sørensen, Vice President Investor Relations & Communications
Phone: +45 33 26 83 83

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE



Comment on this story